IP Library Granted Patent US 9,469,692
Granted Patent B2
US 9,469,692 · App. 14/994,892 · Granted Oct 18, 2016

HER2/neu-specific antibodies and methods of using same

Inventors: Leslie S. Johnson (Darnestown, MD); Ling Huang (Bethesda, MD); Nadine Tuaillon (Smithland, KY); Ezio Bonvini (Potomac, MD)
Assignee: MacroGenics, Inc.
C07K16/32A61K39/39558A61K45/06A61K2039/505C07K2317/24C07K2317/71C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,469,692
App. No.
14/994,892
Granted
Oct 18, 2016
Kind
B2
Abstract

This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

Claims (18)

1. An isolated nucleic acid molecule comprising a sequence encoding a polypeptide comprising:

(A) a light chain variable domain having the amino acid sequence of SEQ ID NO: 4; or

(B) a heavy chain having the amino acid sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 11, and SEQ ID NO: 13.

2. The nucleic acid molecule of claim 1 , wherein the encoded polypeptide comprises the light chain variable domain having the amino acid sequence of SEQ ID NO: 4.

3. The nucleic acid molecule of claim 2 , wherein the encoded polypeptide further comprises a heavy chain having the amino acid sequence of SEQ ID NO: 7.

4. The nucleic acid molecule of claim 1 , wherein the encoded polypeptide comprises the heavy chain having the amino acid sequence of SEQ ID NO: 9.

5. The nucleic acid molecule of claim 4 , wherein the encoded polypeptide further comprises the light chain variable domain having the amino acid sequence of SEQ ID NO: 4.

6. The nucleic acid molecule of claim 1 , wherein the encoded polypeptide comprises the heavy chain having the amino acid sequence of SEQ ID NO: 11.

7. The nucleic acid molecule of claim 6 , wherein the encoded polypeptide further comprises the light chain variable domain having the amino acid sequence of SEQ ID NO: 4.

8. The nucleic acid molecule of claim 1 , wherein the encoded polypeptide comprises the heavy chain having the amino acid sequence of SEQ ID NO: 13.

9. The nucleic acid molecule of claim 8 , wherein the encoded polypeptide further comprises the light chain variable domain having the amino acid sequence of SEQ ID NO: 4.

10. The nucleic acid molecule of claim 1 , wherein the encoded polypeptide is a single chain antibody, a monoclonal antibody, or a diabody.

11. A vector comprising the nucleic acid molecule of claim 1 .

12. The vector of claim 11 which is an expression vector.

13. An isolated host cell comprising the expression vector of claim 12 .

14. A method of producing a substantially purified immunoglobulin or an antigen-binding fragment thereof, comprising the steps of:

a. growing a cell line transformed with the nucleic acid of claim 1 under conditions in which the immunoglobulin or antigen-binding fragment is expressed; and

b. harvesting the expressed immunoglobulin or antigen-binding fragment.

Assignments (5)
RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED AT R/F 069451/0158 Recorded Jan 8, 2025
From: NEWSTONE CAPITAL PARTNERS, LLC
To: TERSERA THERAPEUTICS LLC
Reel/Frame 069840/0730 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2024
From: MACROGENICS, INC.
To: TERSERA THERAPEUTICS LLC
Reel/Frame 069626/0659 →
SECURITY INTEREST Recorded Dec 2, 2024
From: TERSERA THERAPEUTICS LLC
To: NEWSTONE CAPITAL PARTNERS, LLC
Reel/Frame 069451/0158 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded Nov 26, 2024
From: TERSERA THERAPEUTICS LLC
To: ANTARES CAPITAL LP, AS AGENT
Reel/Frame 069447/0210 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2016
From: JOHNSON, LESLIE S.; HUANG, LING; TUAILLON, NADINE; BONVINI, EZIO
To: MACROGENICS, INC.
Reel/Frame 039004/0630 →
Continuity (4)
Continuation 14332239 · Jul 15, 2014
Division 12933885
Provisional Application 61041649 · Apr 2, 2008
Related Publication 20160130360A1 · May 12, 2016